FUNDAMENTALS · Fundamentals · IL Healthcare

Teva Pharmaceutical Industries (TEVA) Fundamentals 2026 — P/E 22.6x, Revenue Analysis | SniperIQ

Teva Pharmaceutical Industries (TEVA) is a IL-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of

5.4B, trading at 0.40 on the NYSE. This SniperIQ fundamentals page covers Teva Pharmaceutical Industries's valuation (P/E 22.6x, P/B 4.3x), profitability (net margin 9.0%), revenue (
7.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
5.4B
P/E (TTM)22.6x
Net Margin9.0%
Revenue (FY25)
7.3B

Full research coverage

Frequently Asked Questions

What is Teva Pharmaceutical Industries's market cap?

Teva Pharmaceutical Industries (TEVA) has a market capitalization of approximately

5.4B, trading at
0.40 on the NYSE. Market cap moves with the live share price.

What is Teva Pharmaceutical Industries's P/E ratio?

Teva Pharmaceutical Industries's trailing twelve-month P/E ratio is 22.6x, with a price-to-book (P/B) of 4.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries runs a net profit margin of 9.0%, a gross margin of 52.1%, and an operating margin of 18.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Teva Pharmaceutical Industries generate?

Teva Pharmaceutical Industries reported revenue of

7.3B for fiscal year 2025, with net income of
.4B and earnings per share (EPS) of 1.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Teva Pharmaceutical Industries pay a dividend?

Teva Pharmaceutical Industries does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Teva Pharmaceutical Industries financially healthy?

Teva Pharmaceutical Industries carries a debt-to-equity ratio of 2.05x and a current ratio of 1.01x, with a market beta of 0.86. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Teva Pharmaceutical Industries a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Teva Pharmaceutical Industries (TEVA) the key facts are: market cap

5.4B, P/E 22.6x, revenue
7.3B, 52-week range 14.99-37.35. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Teva Pharmaceutical Industries's full fundamentals live

Get Teva Pharmaceutical Industries's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.